pamidronate has been researched along with Fibrous Dysplasia of Bone in 17 studies
Fibrous Dysplasia of Bone: A disease of bone marked by thinning of the cortex by fibrous tissue containing bony spicules, producing pain, disability, and gradually increasing deformity. Only one bone may be involved (FIBROUS DYSPLASIA, MONOSTOTIC) or several (FIBROUS DYSPLASIA, POLYOSTOTIC).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thirteen patients with McCune-Albright syndrome (MAS) and bone fibrous dysplasia (BFD) have been treated for 2-6 years with pamidronate, an aminobisphosphonate which inhibits osteoclastic function." | 9.10 | Pamidronate treatment in bone fibrous dysplasia in children and adolescents with McCune-Albright syndrome. ( Altare, F; Andreo, M; de Sanctis, C; Lala, R; Masi, G; Matarazzo, P, 2002) |
| "Pamidronate treatment can ameliorate the course of bone fibrous dysplasia in children and adolescents with McCune-Albright syndrome." | 6.69 | Pamidronate treatment of bone fibrous dysplasia in nine children with McCune-Albright syndrome. ( Bertelloni, S; Buzi, F; de Sanctis, C; Lala, R; Matarazzo, P; Rigon, F, 2000) |
| "Thirteen patients with McCune-Albright syndrome (MAS) and bone fibrous dysplasia (BFD) have been treated for 2-6 years with pamidronate, an aminobisphosphonate which inhibits osteoclastic function." | 5.10 | Pamidronate treatment in bone fibrous dysplasia in children and adolescents with McCune-Albright syndrome. ( Altare, F; Andreo, M; de Sanctis, C; Lala, R; Masi, G; Matarazzo, P, 2002) |
| "Pamidronate treatment can ameliorate the course of bone fibrous dysplasia in children and adolescents with McCune-Albright syndrome." | 2.69 | Pamidronate treatment of bone fibrous dysplasia in nine children with McCune-Albright syndrome. ( Bertelloni, S; Buzi, F; de Sanctis, C; Lala, R; Matarazzo, P; Rigon, F, 2000) |
| "Fibrous dysplasia of bone is a genetic, non-inheritable disease, characterized by bone pain, bone deformities and fracture, involving one or several bones." | 2.44 | Fibrous dysplasia of bone and McCune-Albright syndrome. ( Chapurlat, RD; Orcel, P, 2008) |
| "Fibrous dysplasia of bone is a disease that can involve one or several bones and is characterized by bone deformities, pain and iterative fractures." | 2.41 | Fibrous dysplasia of bone. ( Chapurlat, RD; Meunier, PJ, 2000) |
| "Fibrous dysplasia of bone is characterized by focal replacement of normal bone and marrow with abnormal bone and fibrous tissue." | 1.35 | Nephronophthisis-like nephritis associated with fibrous dysplasia of bone. ( Antignac, C; Bacchetta, J; Bouvier, R; Chapurlat, R; Cochat, P; Delmas, PD; Dubourg, L; Kohler, R, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (23.53) | 18.2507 |
| 2000's | 10 (58.82) | 29.6817 |
| 2010's | 2 (11.76) | 24.3611 |
| 2020's | 1 (5.88) | 2.80 |
| Authors | Studies |
|---|---|
| Chapurlat, R | 3 |
| Legrand, MA | 1 |
| Florez, H | 1 |
| Mandelikova, S | 1 |
| Filella, X | 1 |
| Monegal, A | 1 |
| Guañabens, N | 1 |
| Peris, P | 1 |
| Akasbi, N | 1 |
| Abourazzak, FE | 1 |
| Talbi, S | 1 |
| Tahiri, L | 1 |
| Harzy, T | 1 |
| Bacchetta, J | 1 |
| Bouvier, R | 1 |
| Antignac, C | 1 |
| Dubourg, L | 1 |
| Kohler, R | 1 |
| Delmas, PD | 4 |
| Cochat, P | 1 |
| Matarazzo, P | 2 |
| Lala, R | 2 |
| Masi, G | 1 |
| Andreo, M | 1 |
| Altare, F | 1 |
| de Sanctis, C | 2 |
| Saenger, P | 1 |
| Rincon, M | 1 |
| Parisi, MS | 1 |
| Oliveri, B | 1 |
| Mautalen, CA | 1 |
| Chapurlat, RD | 4 |
| Hugueny, P | 1 |
| Meunier, PJ | 5 |
| Orcel, P | 1 |
| Liens, D | 2 |
| Weinstein, RS | 1 |
| Bertelloni, S | 1 |
| Buzi, F | 1 |
| Rigon, F | 1 |
| Lane, JM | 1 |
| Khan, SN | 1 |
| O'Connor, WJ | 1 |
| Nydick, M | 1 |
| Hommen, JP | 1 |
| Schneider, R | 1 |
| Tomin, E | 1 |
| Brand, J | 1 |
| Curtin, J | 1 |
| Mikosch, P | 1 |
| Pietschmann, P | 1 |
| Kainberger, F | 1 |
| Gallowitsch, HJ | 1 |
| Lind, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Placebo-Controlled Trial of Alendronate in the Treatment of Polyostotic Fibrous Dysplasia and the McCune-Albright Syndrome[NCT00001728] | Phase 2 | 40 participants (Actual) | Interventional | 1998-08-24 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for pamidronate and Fibrous Dysplasia of Bone
| Article | Year |
|---|---|
Fibrous dysplasia of bone and McCune-Albright syndrome.
Topics: Diphosphonates; Fibrous Dysplasia of Bone; Fibrous Dysplasia, Polyostotic; Fractures, Bone; GTP-Bind | 2008 |
Fibrous dysplasia of bone.
Topics: Adolescent; Anti-Inflammatory Agents; Diphosphonates; Fibrous Dysplasia of Bone; Fibrous Dysplasia, | 2000 |
3 trials available for pamidronate and Fibrous Dysplasia of Bone
| Article | Year |
|---|---|
Pamidronate treatment in bone fibrous dysplasia in children and adolescents with McCune-Albright syndrome.
Topics: Adolescent; Adult; Alkaline Phosphatase; Body Height; Bone and Bones; Bone Density; Child; Diphospho | 2002 |
Long-term effects of intravenous pamidronate in fibrous dysplasia of bone.
Topics: Adolescent; Adult; Biomarkers; Biopsy; Bone and Bones; Bone Density; Bone Remodeling; Calcium, Dieta | 1997 |
Pamidronate treatment of bone fibrous dysplasia in nine children with McCune-Albright syndrome.
Topics: Adolescent; Bone Density; Child; Child, Preschool; Diphosphonates; Female; Fibrous Dysplasia of Bone | 2000 |
12 other studies available for pamidronate and Fibrous Dysplasia of Bone
| Article | Year |
|---|---|
Bisphosphonates for the treatment of fibrous dysplasia of bone.
Topics: Bone and Bones; Diphosphonates; Fibrous Dysplasia of Bone; Humans; Pamidronate; Quality of Life | 2021 |
Clinical significance of increased serum levels of FGF-23 in fibrous dysplasia.
Topics: Adult; Aged; Alendronate; Biomarkers; Bone Density Conservation Agents; Female; Fibroblast Growth Fa | 2018 |
[Fibrous dysplasia: overview].
Topics: Bone Density Conservation Agents; Chromogranins; Diphosphonates; Fibrous Dysplasia of Bone; GTP-Bind | 2015 |
Nephronophthisis-like nephritis associated with fibrous dysplasia of bone.
Topics: Child; Diphosphonates; Fibrous Dysplasia of Bone; Humans; Kidney; Male; Nephritis; Pamidronate | 2008 |
Precocious puberty: McCune-Albright syndrome and beyond.
Topics: Anti-Inflammatory Agents; Central Nervous System Neoplasms; Child; Child, Preschool; Diphosphonates; | 2003 |
Effect of intravenous pamidronate on bone markers and local bone mineral density in fibrous dysplasia.
Topics: Adolescent; Adult; Alkaline Phosphatase; Bone Density; Case-Control Studies; Collagen; Collagen Type | 2003 |
Treatment of fibrous dysplasia of bone with intravenous pamidronate: long-term effectiveness and evaluation of predictors of response to treatment.
Topics: Administration, Oral; Adolescent; Adult; Biomarkers; Bone and Bones; Bone Density; Bone Remodeling; | 2004 |
Long-term effects of intravenous pamidronate in fibrous dysplasia of bone.
Topics: Adolescent; Adult; Alkaline Phosphatase; Diphosphonates; Female; Fibrous Dysplasia of Bone; Follow-U | 1994 |
Long-term aminobisphosphonate treatment of fibrous dysplasia: spectacular increase in bone density.
Topics: Adult; Bone Density; Calcium, Dietary; Collagen; Collagen Type I; Diphosphonates; Female; Fibrous Dy | 1997 |
The nonsurgical treatment of fibrous dysplasia.
Topics: Adolescent; Bone Density; Calcium; Diphosphonates; Ergocalciferols; Female; Fibrous Dysplasia of Bon | 1999 |
Bisphosphonate therapy in fibrous dysplasia.
Topics: Administration, Oral; Adult; Aged; Alendronate; Biomarkers; Bone and Bones; Collagen; Collagen Type | 2001 |
[Paget disease or fibrous dysplasia of the radius?--A case report].
Topics: Diagnosis, Differential; Diphosphonates; Dose-Response Relationship, Drug; Drug Administration Sched | 2001 |